by Micah Harman | Mar 12, 2024 | Press Releases
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET LEHI, Utah, March 12, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule... by Micah Harman | Feb 21, 2024 | Press Releases
LEHI, Utah, Feb. 21, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of... by Micah Harman | Feb 15, 2024 | Press Releases
The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/... 
by Halia Therapeutics | Feb 6, 2024 | Press Releases
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2) LEHI,... 
by Halia Therapeutics | Jan 31, 2024 | Press Releases
Series C Financing will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, January 31,... by Halia Therapeutics | Jan 4, 2024 | Press Releases
LEHI, Utah, Jan. 4, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation. Today, the company announced that its leadership team will attend... by Halia Therapeutics | Dec 15, 2023 | Press Releases
LEHI, Utah, Dec. 15, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will present at the 13th... 
by Halia Therapeutics | Dec 13, 2023 | Press Releases
LEHI, Utah, Dec. 13, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical... 
by Halia Therapeutics | Dec 8, 2023 | Press Releases, News & Media
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early... 
by Halia Therapeutics | Nov 29, 2023 | News & Media, Press Releases
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the... by Halia Therapeutics | Nov 27, 2023 | Press Releases
Halia will present 3 posters with new positive data and a company showcase providing an overview of its clinical programs targeting the inflammasome LEHI, Utah, Nov. 27, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company... 
by Halia Therapeutics | Nov 20, 2023 | Press Releases
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced... 
by Halia Therapeutics | Nov 16, 2023 | Press Releases
SALT LAKE CITY, Nov. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the... 
by Halia Therapeutics | Oct 31, 2023 | Press Releases
Company announces the appointment of Dr. David Bearss, CEO of Halia Therapeutics, as a member of the Board of Directors at BioUtah LEHI, Utah, Oct. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative... by Halia Therapeutics | Oct 18, 2023 | Press Releases
LEHI, Utah, Oct. 18, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that Jared Bearss,... by Halia Therapeutics | Aug 31, 2023 | Press Releases
SALT LAKE CITY, Aug. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they... 
by Halia Therapeutics | Aug 22, 2023 | Press Releases
The company plans to start two Phase II trials later this year, with a further Phase I trial planned for early 2024. Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss in an... by Halia Therapeutics | Aug 16, 2023 | Press Releases
SALT LAKE CITY, Aug. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the opening of its... by Halia Therapeutics | Aug 7, 2023 | Press Releases
– Halia expects to release data from the Phase I trial in Q4 2023 SALT LAKE CITY, Aug. 7, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases that are driven... by Halia Therapeutics | Feb 9, 2023 | Press Releases
Halia is excited to announce that Anya Neidig, MSN, RN, has joined our clinical team as Director of Clinical Operations. Anya brings over 20 years of experience in patient care and will help advance our #NEK7 and #LRRK2 programs through multiple clinical trials in...